Cargando…
Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) a...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766866/ https://www.ncbi.nlm.nih.gov/pubmed/30637852 http://dx.doi.org/10.1002/jmri.26612 |
_version_ | 1783454785947566080 |
---|---|
author | Vietti Violi, Naïk Hilbert, Tom Bastiaansen, Jessica A.M. Knebel, Jean‐Francois Ledoux, Jean‐Baptiste Stemmer, Alto Meuli, Reto Kober, Tobias Schmidt, Sabine |
author_facet | Vietti Violi, Naïk Hilbert, Tom Bastiaansen, Jessica A.M. Knebel, Jean‐Francois Ledoux, Jean‐Baptiste Stemmer, Alto Meuli, Reto Kober, Tobias Schmidt, Sabine |
author_sort | Vietti Violi, Naïk |
collection | PubMed |
description | BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) analysis in the pancreas and correlate T(2)‐values with age, body mass index, pancreatic location, main pancreatic duct dilatation, and underlying pathology. STUDY TYPE: Retrospective single‐center pilot study. POPULATION: Eighty‐eight adults. FIELD STRENGTH/SEQUENCE: Ten‐fold accelerated multiecho‐spin‐echo 3 T MRI sequence to quantify T(2) at 3 T. ASSESSMENT: Two radiologists independently delineated three regions of interest inside the pancreatic head, body, and tail for each acquisition. Means and standard deviations for T(2) values in these regions were determined. T(2)‐value variation with demographic data, intraparenchymal location, pancreatic duct dilation, and underlying pancreatic disease was assessed. STATISTICAL TESTS: Interreader reliability was determined by calculating the interclass coefficient (ICCs). T(2) values were compared for different pancreatic locations by analysis of variance (ANOVA). Interpatient associations between T(2) values and demographical, clinical, and radiological data were calculated (ANOVA). RESULTS: The accelerated T(2) mapping sequence was successfully performed in all participants (mean acquisition time, 2:48 ± 0:43 min). Low T(2) value variability was observed across all patients (intersubject) (head: 60.2 ± 8.3 msec, body: 63.9 ± 11.5 msec, tail: 66.8 ± 16.4 msec). Interreader agreement was good (ICC, 0.82, 95% confidence interval: 0.77–0.86). T(2)‐values differed significantly depending on age (P < 0.001), location (P < 0.001), main pancreatic duct dilatation (P < 0.001), and diffuse pancreatic disease (P < 0.03). DATA CONCLUSION: The feasibility of accelerated T(2) mapping at 3 T in moving abdominal organs was demonstrated in the pancreas, since T(2) values were stable and reproducible. In the pancreatic parenchyma, T(2)‐values were significantly dependent on demographic and clinical parameters. Level of Evidence: 4 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:410–416. |
format | Online Article Text |
id | pubmed-6766866 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67668662019-10-01 Patient respiratory‐triggered quantitative T(2) mapping in the pancreas Vietti Violi, Naïk Hilbert, Tom Bastiaansen, Jessica A.M. Knebel, Jean‐Francois Ledoux, Jean‐Baptiste Stemmer, Alto Meuli, Reto Kober, Tobias Schmidt, Sabine J Magn Reson Imaging Original Research BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) analysis in the pancreas and correlate T(2)‐values with age, body mass index, pancreatic location, main pancreatic duct dilatation, and underlying pathology. STUDY TYPE: Retrospective single‐center pilot study. POPULATION: Eighty‐eight adults. FIELD STRENGTH/SEQUENCE: Ten‐fold accelerated multiecho‐spin‐echo 3 T MRI sequence to quantify T(2) at 3 T. ASSESSMENT: Two radiologists independently delineated three regions of interest inside the pancreatic head, body, and tail for each acquisition. Means and standard deviations for T(2) values in these regions were determined. T(2)‐value variation with demographic data, intraparenchymal location, pancreatic duct dilation, and underlying pancreatic disease was assessed. STATISTICAL TESTS: Interreader reliability was determined by calculating the interclass coefficient (ICCs). T(2) values were compared for different pancreatic locations by analysis of variance (ANOVA). Interpatient associations between T(2) values and demographical, clinical, and radiological data were calculated (ANOVA). RESULTS: The accelerated T(2) mapping sequence was successfully performed in all participants (mean acquisition time, 2:48 ± 0:43 min). Low T(2) value variability was observed across all patients (intersubject) (head: 60.2 ± 8.3 msec, body: 63.9 ± 11.5 msec, tail: 66.8 ± 16.4 msec). Interreader agreement was good (ICC, 0.82, 95% confidence interval: 0.77–0.86). T(2)‐values differed significantly depending on age (P < 0.001), location (P < 0.001), main pancreatic duct dilatation (P < 0.001), and diffuse pancreatic disease (P < 0.03). DATA CONCLUSION: The feasibility of accelerated T(2) mapping at 3 T in moving abdominal organs was demonstrated in the pancreas, since T(2) values were stable and reproducible. In the pancreatic parenchyma, T(2)‐values were significantly dependent on demographic and clinical parameters. Level of Evidence: 4 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:410–416. John Wiley and Sons Inc. 2019-01-13 2019-08 /pmc/articles/PMC6766866/ /pubmed/30637852 http://dx.doi.org/10.1002/jmri.26612 Text en © 2019 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Research Vietti Violi, Naïk Hilbert, Tom Bastiaansen, Jessica A.M. Knebel, Jean‐Francois Ledoux, Jean‐Baptiste Stemmer, Alto Meuli, Reto Kober, Tobias Schmidt, Sabine Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title | Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title_full | Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title_fullStr | Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title_full_unstemmed | Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title_short | Patient respiratory‐triggered quantitative T(2) mapping in the pancreas |
title_sort | patient respiratory‐triggered quantitative t(2) mapping in the pancreas |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766866/ https://www.ncbi.nlm.nih.gov/pubmed/30637852 http://dx.doi.org/10.1002/jmri.26612 |
work_keys_str_mv | AT viettiviolinaik patientrespiratorytriggeredquantitativet2mappinginthepancreas AT hilberttom patientrespiratorytriggeredquantitativet2mappinginthepancreas AT bastiaansenjessicaam patientrespiratorytriggeredquantitativet2mappinginthepancreas AT knebeljeanfrancois patientrespiratorytriggeredquantitativet2mappinginthepancreas AT ledouxjeanbaptiste patientrespiratorytriggeredquantitativet2mappinginthepancreas AT stemmeralto patientrespiratorytriggeredquantitativet2mappinginthepancreas AT meulireto patientrespiratorytriggeredquantitativet2mappinginthepancreas AT kobertobias patientrespiratorytriggeredquantitativet2mappinginthepancreas AT schmidtsabine patientrespiratorytriggeredquantitativet2mappinginthepancreas |